2020
Overview
Convalescent plasma therapy is an experimental treatment for Covid-19. It involves collecting plasma from individuals who have recovered from Covid-19, which contains antibodies against the virus. The plasma is then transfused into patients who are currently suffering from the disease, providing them with passive immunity. Convalescent plasma therapy has been used successfully in the past to treat other viral infections, and there are several ongoing clinical trials investigating its efficacy against Covid-19. Some preliminary results have shown that convalescent plasma therapy may be an effective treatment for severely ill Covid-19 patients. However, there are also some potential risks and limitations associated with the therapy. For example, the quality and quantity of antibodies in the donated plasma can vary between donors, and it is unclear how much plasma is required to achieve a therapeutic effect. Additionally, transfusing plasma from other individuals carries the risk of transmitting other viruses or infections. Despite these caveats, convalescent plasma therapy remains a promising area of research in the fight against Covid-19. As more data is collected from clinical trials, researchers will gain a better understanding of its efficacy and limitations, and it may become an important tool in the treatment of severely ill patients. Overall, convalescent plasma therapy holds potential for mitigating the effects of Covid-19, reducing mortality rates and easing the burden on healthcare systems around the world.
Research published in this journal
1 peer-reviewed article, ranked by relevance. Each links to its DOI.
How this research is being cited
The 1 article above has been cited 4 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Oct 2025.
-
2021 · SN Computer Science
-
2021 ·
-
Xin Qian et al. · 2020 · CHI Extended Abstracts
-
2020 ·
A sample of recent works citing this journal's research on Covid-19 Convalescent Plasma, linking to each citing work.